Moderna Flu Shot Application Initially Refused Then Reversed by FDA
The FDA initially refused to consider Moderna’s seasonal influenza mRNA vaccine application in February without detailed public explanation, then reversed that stance days later and resumed formal review. CBER head Dr. Vinay Prasad will step down at the end of April, potentially altering regulatory review processes for mRNA-based therapies.
1. Initial Refusal of Moderna’s Flu Shot Application
The FDA’s Center for Biologics Evaluation and Research initially refused in February to consider Moderna’s seasonal influenza mRNA vaccine application without detailed public explanation, then reversed that stance days later and resumed formal review.
2. CBER Leadership Change and Implications for Moderna
Dr. Vinay Prasad will step down as CBER director at the end of April, creating uncertainty over regulatory timelines and data requirements for Moderna’s flu shot and other mRNA-based therapies under the agency’s oversight.